Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP7374 vs Egg-derived TIV for Influenza in Adults
NCT01961947Phase 3Completed
- Sponsor
- UMN Pharma Inc.
- Start
- Oct 2013
- Primary completion
- Nov 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ASP7374 in influenza (2 arms), sponsored by UMN Pharma Inc. Primary endpoints: seroconversion rate of hemagglutination inhibition (HI) antibody titer at Day 29 and geometric mean titer (GMT) of HI antibody titer at Day 29. Started Oct 2013; status: completed.
02
Drugs
ASP7374
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01961947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961947.